

Claims

1. A solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient ("API") which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound:



A1



A2


wherein

A is $COOR_5$, $OPO(OR_5)_2$, $PO(OR_5)_2$, SO_2OR_5, POR_5OR_5 or 1*H*-tetrazol-5-yl, R_5 being H or an ester-forming group;

W is a bond, C_{1-3}alkylene or C_{2-3}alkenylene;

Y is C_{6-10}aryl or C_{3-9}heteroaryl, optionally substituted by 1 to 3 radicals selected from halogen, NO_2, C_{1-6}alkyl, C_{1-6}alkoxy; halo-substituted C_{1-6}alkyl and halo-substituted C_{1-6}alkoxy;

Z is chosen from:



wherein the asterisks of Z indicate the point of attachment between -C(R_3)(R_4)- and A of Formula Ia or Ib, respectively; R_6 is chosen from hydrogen and C_{1-6}alkyl; and J_1 and J_2 are independently methylene or a heteroatom chosen from S, O and NR_5; wherein R_5 is chosen from hydrogen and C_{1-6}alkyl; and any alkylene of Z can be further substituted by one to three radicals chosen from halo, hydroxy, C_{1-6}alkyl; or R_6 can be attached to a carbon atom of Y to form a 5-7 member ring;

R_1 is C_{6-10}aryl or C_{3-9}heteroaryl, optionally substituted by C_{1-6}alkyl, C_{6-10}aryl, C_{6-10}arylC_{1-4}alkyl, C_{3-9}heteroaryl, C_{3-9}heteroarylC_{1-4}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkylC_{1-4}alkyl, C_{3-8}heterocycloalkyl or C_{3-8}heterocycloalkylC_{1-4}alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_1 may be substituted by 1 to 5 groups selected from halogen, C_{1-6}alkyl, C_{1-6}alkoxy and halo substituted-C_{1-6}alkyl or -C_{1-6}alkoxy;

R_2 is H, C_{1-6}alkyl, halo substituted C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl; and

each of R_3 or R_4, independently, is H, halogen, OH, C_{1-6}alkyl, C_{1-6}alkoxy or halo substituted C_{1-6}alkyl or C_{1-6}alkoxy.

2. A composition of claim 1 wherein A is COOH.

3. A composition of claim 1 wherein the API is 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a pharmaceutically acceptable salt.

4. A composition of claim 1 wherein the API is 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a hemifumarate salt thereof.

5. A composition of any preceding claim wherein the API is in a mixture of materials which is free of basic compounds.

6. A solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient ("API") selected from the compounds as defined in any of claims 1 to 4, wherein the API is in the form of particles having an X90 diameter of at least 8μm.

7. A composition of claim 6 wherein the particles have an X90 diameter of from 10μm to 300μm.

8. A composition of any of claims 6 or 7 which is in unit dosage form and complies with the US Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia harmonised content uniformity requirements as in force on 1 January 2011.

9. A solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient ("API") selected from the compounds as defined in any of claims 1 to 4, wherein the API has a crystallinity of 80% or more.

10. A tablet comprising a compressed mixture consisting of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof and one or more non-basic excipients, the 1-{4-[1-

(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or pharmaceutically acceptable salt being in the form of particles having an X90 diameter of from 10 µm to 200 µm.

11. A tablet of claim 10, wherein the pharamaceutically acceptable salt is a hemifumarate salt.

12. A tablet of claim 10 or 11 wherein said particles are at least 80% crystalline.

13. A tablet of claim 10, 11 or claim 12 wherein the compressed mixture includes a desiccant and is coated with a moisture barrier.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient ("API") which is 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the API is in a mixture of materials which is free of basic compounds.

2. A composition of claim 1 wherein the API is 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a hemifumarate salt thereof.

3. A solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient ("API") selected from the compounds as defined in claim 1 or 2, wherein the API is in the form of particles having an X90 diameter of at least 8µm.

4. A composition of claim 3 wherein the particles have an X90 diameter of from 10µm to 300µm.

5. A solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient ("API") selected from the compounds as defined claim 1 or 2, wherein the API has a crystallinity of 80% or more.

6. A tablet comprising a compressed mixture consisting of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof and one or more non-basic excipients, the 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or pharmaceutically acceptable salt being in the form of particles having an X90 diameter of from 10 µm to 200 µm wherein the 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof is not in admixture with a basic compound.

7. A tablet of claim 6, wherein the pharamaceutically acceptable salt is a hemifumarate salt.

8. A tablet of claim 6 or 7 wherein said particles are at least 80% crystalline.

9. A tablet of any one of claims 6 to 8 wherein the compressed mixture includes a desiccant and is coated with a moisture barrier.